| Name | Fluvastatin sodium |
| Description | Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol lowering agent. |
| In vitro | In a rabbit model, daily administration of Fluvastatin (10 mg/kg) significantly reversed the inhibition of acetylcholine-induced vasodilation, effectively reducing hyperlipidemia. |
| In vivo | In human aortic smooth muscle cells, Fluvastatin (100 nM) reduces the formation of superoxide anion radicals activated by angiotensin II. In CHL/IU cells, Fluvastatin (8 μM) offers protection against DNA damage. It significantly inhibits the formation of thiobarbituric acid-reactive substances in lipid peroxidation initiated by divalent iron ions (IC50=12 μM). Fluvastatin (1-100 μM) can inhibit lipid peroxidation mediated by peroxyl radicals induced by 2,2'-azobis(2-amidinopropane) dihydrochloride and 2,2'-azobis. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10.8 mg/mL (25 mM)
DMSO : 43.3 mg/mL (100 mM)
|
| Keywords | Inhibitor | HMG-CoA Reductase (HMGCR) | Nrf2-dependent | muscle | pathway | HMG-CoA | Autophagy | smooth | inhibit | antioxidant | XU 62-320 | stress | reductase | Fluvastatin | vascular | oxidative | Fluvastatin sodium | Ferroptosis |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Paeonol | L-Cystine | Naringin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Oxidation-Reduction Compound Library |
United States
